{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T12:05:05Z","timestamp":1784721905314,"version":"3.55.0"},"reference-count":52,"publisher":"Institute of Physiology of the Czech Academy of Sciences","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Physiol Res"],"abstract":"<jats:p>The aim of this study was to determine the effect of rosuvastatin (10 mg\/kg\/day, p.o.) on the flinching nociceptive behavior produced by subcutaneous injection of 0.5 % formalin in the dorsum of the right hind paw from Wistar rats submitted to \na 16-week treatment, including a standard rat chow diet \n(STD-diet) or a high fat-diet (HF-diet). At three days post-treatment, the formalin-induced nociceptive response was assessed for 1 h. Compared to the STD-diet, the HF-diet significantly increased the number of flinches in the second phase of the formalin test, as well as inducing higher body weight and levels of glucose, total cholesterol, triglycerides, insulin and blood pressure. Rosuvastatin significantly decreased the formalin-induced nociceptive behavior after both diets and significantly reduced those metabolic parameters in rats with a HF- but not STD-diet.<\/jats:p>","DOI":"10.33549\/physiolres.935681","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:49:07Z","timestamp":1784720947000},"page":"585","source":"Crossref","is-referenced-by-count":0,"title":["The Effect of Rosuvastatin on Formalin-Induced Nociceptive Behavior in an Experimental Rat Model of Metabolic Syndrome"],"prefix":"10.33549","author":[{"given":"M","family":"Garc\u00eda-Paz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"L\u00f3pez-Canales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Toledo-Blas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Franco-Vadillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Flores-Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"L\u00f3pez-Canales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Paredes-Carbajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Lozano-Cuenca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"19169","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1.\tLim S, Eckel RH. Pharmacological treatment and therapeutic perspectives of metabolic syndrome. Rev Endocr Metab Disord 2014;15:329-341. https:\/\/doi.org\/10.1007\/s11154-014-9298-4","DOI":"10.1007\/s11154-014-9298-4"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.\tVincent AM, Hayes JM, McLean LL, Vivekanandan-Giri A, Pennathur S, Feldman EL. Dyslipidemia-induced neuropathy in mice: the role of oxLDL\/LOX-1. Diabetes 2009;58:2376-2385. https:\/\/doi.org\/10.2337\/db09-0047","DOI":"10.2337\/db09-0047"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.\tVincent AM, Hinder LM, Pop-Busui R, Feldman EL. Hyperlipidemia: a new therapeutic target for diabetic neuropathy. J Peripher Nerv Syst 2009;14:257-267. https:\/\/doi.org\/10.1111\/j.1529-8027.2009.00237.x","DOI":"10.1111\/j.1529-8027.2009.00237.x"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.\tCourteix C, Eschalier A, Lavarenne J. Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain. Pain 1993;53:81-88. https:\/\/doi.org\/10.1016\/0304-3959(93)90059-X","DOI":"10.1016\/0304-3959(93)90059-X"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5.\tSugimoto K, Rashid IB, Kojima K, Shoji M, Tanabe J, Tamasawa N, et al. Time course of pain sensation in rat models of insulin resistance, type 2 diabetes, and exogenous hyperinsulinaemia. Diabetes Metab Res Rev 2008;24:642-650. https:\/\/doi.org\/10.1002\/dmrr.903","DOI":"10.1002\/dmrr.903"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6.\tHan L, Ji L, Chang J, Wen J, Zhao W, Shi H, et al. Peripheral neuropathy is associated with insulin resistance independent of metabolic syndrome. Diabetol Metab Syndr 2015;7:14. https:\/\/doi.org\/10.1186\/s13098-015-0010-y","DOI":"10.1186\/s13098-015-0010-y"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.\tCallaghan BC, Xia R, Reynolds E, Banerjee M, Rothberg AE, Burant CF, et al. Association Between Metabolic Syndrome Components and Polyneuropathy in an Obese Population. JAMA Neurol 2016;73:1468-1476. https:\/\/doi.org\/10.1001\/jamaneurol.2016.3745","DOI":"10.1001\/jamaneurol.2016.3745"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8.\tLoredo-Perez AA, Montalvo-Blanco CE, Hernandez-Gonzalez LI, Anaya-Reyes M, Fernandez Del Valle-Laisequilla C, Reyes-Garcia JG, et al. High-fat diet exacerbates pain-like behaviors and periarticular bone loss in mice with CFA-induced knee arthritis. Obesity (Silver Spring) 2016;24:1106-1115. https:\/\/doi.org\/10.1002\/oby.21485","DOI":"10.1002\/oby.21485"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9.\tShin D. Association between metabolic syndrome, radiographic knee osteoarthritis, and intensity of knee pain: results of a national survey. J Clin Endocrinol Metab 2014;99:3177-3183. https:\/\/doi.org\/10.1210\/jc.2014-1043","DOI":"10.1210\/jc.2014-1043"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10.\tSong Z, Xie W, Chen S, Strong JA, Print MS, Wang JI, et al. High-fat diet increases pain behaviors in rats with or without obesity. Sci Rep 2017;7:10350. https:\/\/doi.org\/10.1038\/s41598-017-10458-z","DOI":"10.1038\/s41598-017-10458-z"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11.\tLopez-Canales JS, Lozano-Cuenca J, Lopez-Canales OA, Aguilar-Carrasco JC, Aranda-Zepeda L, Lopez-Sanchez P, et al. Pharmacological characterization of mechanisms involved in the vasorelaxation produced by rosuvastatin in aortic rings from rats with a cafeteria-style diet. Clin Exp Pharmacol Physiol 2015;42:653-661. https:\/\/doi.org\/10.1111\/1440-1681.12406","DOI":"10.1111\/1440-1681.12406"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12.\tDelsing DJ, Post SM, Groenendijk M, Solaas K, van der Boom H, van Duyvenvoorde W, et al. Rosuvastatin reduces plasma lipids by inhibiting VLDL production and enhancing hepatobiliary lipid excretion in ApoE*3-leiden mice. J Cardiovasc Pharmacol 2005;45:53-60. https:\/\/doi.org\/10.1097\/00005344-200501000-00010","DOI":"10.1097\/00005344-200501000-00010"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13.\tDubuisson D, Dennis SG. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain 1977;4:161-174. https:\/\/doi.org\/10.1016\/0304-3959(77)90130-0","DOI":"10.1016\/0304-3959(77)90130-0"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14.\tWheeler-Aceto H, Cowan A. Standardization of the rat paw formalin test for the evaluation of analgesics. Psychopharmacology (Berl) 1991;104:35-44. https:\/\/doi.org\/10.1007\/BF02244551","DOI":"10.1007\/BF02244551"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15.\tRossi HL, Luu AK, DeVilbiss JL, Recober A. Obesity increases nociceptive activation of the trigeminal system. Eur J Pain 2013;17:649-653. https:\/\/doi.org\/10.1002\/j.1532-2149.2012.00230.x","DOI":"10.1002\/j.1532-2149.2012.00230.x"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16.\tZhang Y, Song C, Li H, Hou J, Li D. Ursolic acid prevents augmented peripheral inflammation and inflammatory hyperalgesia in high-fat diet-induced obese rats by restoring downregulated spinal PPARalpha. Mol Med Rep 2016;13:5309-5316. https:\/\/doi.org\/10.3892\/mmr.2016.5172","DOI":"10.3892\/mmr.2016.5172"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17.\tvan der Heijden RA, Sheedfar F, Morrison MC, Hommelberg PP, Kor D, Kloosterhuis NJ, et al. High-fat diet induced obesity primes inflammation in adipose tissue prior to liver in C57BL\/6j mice. Aging (Albany NY) 2015;7:256-268. https:\/\/doi.org\/10.18632\/aging.100738","DOI":"10.18632\/aging.100738"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18.\tLee S, Lee Y, Kim J, An J, Kim K, Lee H, et al. Atorvastatin and rosuvastatin improve physiological parameters and alleviate immune dysfunction in metabolic disorders. Biochem Biophys Res Commun 2016;478:1242-1247. https:\/\/doi.org\/10.1016\/j.bbrc.2016.08.101","DOI":"10.1016\/j.bbrc.2016.08.101"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19.\tYu Y, Ohmori K, Chen Y, Sato C, Kiyomoto H, Shinomiya K, et al. Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model. J Am Coll Cardiol 2004;44:904-913. https:\/\/doi.org\/10.1016\/j.jacc.2004.04.050","DOI":"10.1016\/j.jacc.2004.04.050"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20.\tRidker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207. https:\/\/doi.org\/10.1056\/NEJMoa0807646","DOI":"10.1056\/NEJMoa0807646"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21.\tWaters DD, Ho JE, DeMicco DA, Breazna A, Arsenault BJ, Wun CC, et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol 2011;57:1535-1545. https:\/\/doi.org\/10.1016\/j.jacc.2010.10.047","DOI":"10.1016\/j.jacc.2010.10.047"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22.\tPreiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011;305:2556-2564. https:\/\/doi.org\/10.1001\/jama.2011.860","DOI":"10.1001\/jama.2011.860"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"23.\tSaito Y, Yamada N, Shirai K, Sasaki J, Ebihara Y, Yanase T, Fox JC. Effect of rosuvastatin 5-20mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemia. Atherosclerosis 2007;194:505-511. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2006.11.028","DOI":"10.1016\/j.atherosclerosis.2006.11.028"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"24.\tRafeeq MM, Habib HS, Murad H, Gari MA, Gazzaz ZJ. Effect of rosuvastatin on dyslipidemia and other parameters associated with metabolic syndrome in Saudi patients. Niger J Clin Pract 2017;20:445-453. https:\/\/doi.org\/10.4103\/1119-3077.197021","DOI":"10.4103\/1119-3077.197021"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"25.\tChamberlain LH. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett 2001;507:357-361. https:\/\/doi.org\/10.1016\/S0014-5793(01)03007-1","DOI":"10.1016\/S0014-5793(01)03007-1"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"26.\tYada T, Nakata M, Shiraishi T, Kakei M. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol 1999;126:1205-1213. https:\/\/doi.org\/10.1038\/sj.bjp.0702397","DOI":"10.1038\/sj.bjp.0702397"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"27.\tSalunkhe VA, Elvstam O, Eliasson L, Wendt A. Rosuvastatin treatment affects both basal and glucose-induced insulin secretion in INS-1 832\/13 Cells. PLoS One 2016;11:e0151592. https:\/\/doi.org\/10.1371\/journal.pone.0151592","DOI":"10.1371\/journal.pone.0151592"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"28.\tSalunkhe VA, Mollet IG, Ofori JK, Malm HA, Esguerra JL, Reinbothe TM, et al. Dual effect of rosuvastatin on glucose homeostasis through improved insulin sensitivity and reduced insulin secretion. EBioMedicine 2016;10:185-194. https:\/\/doi.org\/10.1016\/j.ebiom.2016.07.007","DOI":"10.1016\/j.ebiom.2016.07.007"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"29.\tYao C, Xue X, Jia Y, Li M, Zhang L, Yuan H, et al. Rosuvastatin ameliorates obesity-associated insulin resistance in high-fat diet-fed mice by modulating the gut microbiota and gut metabolites. Front Cell Infect Microbiol 2025;15:1593581. https:\/\/doi.org\/10.3389\/fcimb.2025.1593581","DOI":"10.3389\/fcimb.2025.1593581"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"30.\tTocci G, Presta V, Citoni B, Figliuzzi I, Coluccia R, Battistoni A, et al. Favourable impact of statin use on diastolic blood pressure levels: analysis of a large database of 24-hour ambulatory blood pressure monitoring. J Hypertens 2017;35:2086-2094. https:\/\/doi.org\/10.1097\/HJH.0000000000001419","DOI":"10.1097\/HJH.0000000000001419"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"31.\tFeron O, Dessy C, Desager JP, Balligand JL. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001;103:113-118. https:\/\/doi.org\/10.1161\/01.CIR.103.1.113","DOI":"10.1161\/01.CIR.103.1.113"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"32.\tO'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997;95:1126-1131. https:\/\/doi.org\/10.1161\/01.CIR.95.5.1126","DOI":"10.1161\/01.CIR.95.5.1126"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"33.\tGhaisas MM, Dandawate PR, Zawar SA, Ahire YS, Gandhi SP. Antioxidant, antinociceptive and anti-inflammatory activities of atorvastatin and rosuvastatin in various experimental models. Inflammopharmacology 2010;18:169-177. https:\/\/doi.org\/10.1007\/s10787-010-0044-6","DOI":"10.1007\/s10787-010-0044-6"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"34.\tShi XQ, Lim TK, Lee S, Zhao YQ, Zhang J. Statins alleviate experimental nerve injury-induced neuropathic pain. Pain 2011;152:1033-1043. https:\/\/doi.org\/10.1016\/j.pain.2011.01.006","DOI":"10.1016\/j.pain.2011.01.006"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"35.\tHunskaar S, Hole K. The formalin test in mice: dissociation between inflammatory and non-inflammatory pain. Pain 1987;30:103-114. https:\/\/doi.org\/10.1016\/0304-3959(87)90088-1","DOI":"10.1016\/0304-3959(87)90088-1"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"36.\tMoore PK, Oluyomi AO, Babbedge RC, Wallace P, Hart SL. L-NG-nitro arginine methyl ester exhibits antinociceptive activity in the mouse. Br J Pharmacol 1991;102:198-202. https:\/\/doi.org\/10.1111\/j.1476-5381.1991.tb12153.x","DOI":"10.1111\/j.1476-5381.1991.tb12153.x"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"37.\tMurray CW, Porreca F, Cowan A. Methodological refinements to the mouse paw formalin test. An animal model of tonic pain. J Pharmacol Methods 1988;20:175-186. https:\/\/doi.org\/10.1016\/0160-5402(88)90078-2","DOI":"10.1016\/0160-5402(88)90078-2"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"38.\tWheeler-Aceto H, Cowan A. Neurogenic and tissue-mediated components of formalin-induced edema: evidence for supraspinal regulation. Agents Actions 1991;34:264-269. https:\/\/doi.org\/10.1007\/BF01993299","DOI":"10.1007\/BF01993299"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"39.\tGabay E, Wolf G, Shavit Y, Yirmiya R, Tal M. Chronic blockade of interleukin-1 (IL-1) prevents and attenuates neuropathic pain behavior and spontaneous ectopic neuronal activity following nerve injury. Eur J Pain 2011;15:242-248. https:\/\/doi.org\/10.1016\/j.ejpain.2010.07.012","DOI":"10.1016\/j.ejpain.2010.07.012"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"40.\tSong Z, Xie W, Chen S, Strong JA, Print MS, Wang JI, et al. High-fat diet increases pain behaviors in rats with or without obesity. Sci Rep 2017;7:10350. https:\/\/doi.org\/10.1038\/s41598-017-10458-z","DOI":"10.1038\/s41598-017-10458-z"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"41.\tXie WR, Deng H, Li H, Bowen TL, Strong JA, Zhang JM. Robust increase of cutaneous sensitivity, cytokine production and sympathetic sprouting in rats with localized inflammatory irritation of the spinal ganglia. Neuroscience 2006;142:809-822. https:\/\/doi.org\/10.1016\/j.neuroscience.2006.06.045","DOI":"10.1016\/j.neuroscience.2006.06.045"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"42.\tShen S, Lim G, You Z, Ding W, Huang P, Ran C, et al. Gut microbiota is critical for the induction of chemotherapy-induced pain. Nat Neurosci 2017;20:1213-1216. https:\/\/doi.org\/10.1038\/nn.4606","DOI":"10.1038\/nn.4606"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"43.\tWang J, Zhang Q, Zhao L, Li D, Fu Z, Liang L. Down-regulation of PPARalpha in the spinal cord contributes to augmented peripheral inflammation and inflammatory hyperalgesia in diet-induced obese rats. Neuroscience 2014;278:165-178. https:\/\/doi.org\/10.1016\/j.neuroscience.2014.07.071","DOI":"10.1016\/j.neuroscience.2014.07.071"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"44.\tCameron N, Cotter M, Inkster M, Nangle M. Looking to the future: diabetic neuropathy and effects of rosuvastatin on neurovascular function in diabetes models. Diabetes Res Clin Pract 2003;61(Suppl 1):S35-S39. https:\/\/doi.org\/10.1016\/S0168-8227(03)00123-2","DOI":"10.1016\/S0168-8227(03)00123-2"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"45.\tOhsawa M, Aasato M, Hayashi SS, Kamei J. RhoA\/Rho kinase pathway contributes to the pathogenesis of thermal hyperalgesia in diabetic mice. Pain 2011;152:114-122. https:\/\/doi.org\/10.1016\/j.pain.2010.10.005","DOI":"10.1016\/j.pain.2010.10.005"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"46.\tMorgenweck J, Abdel-Aleem OS, McNamara KC, Donahue RR, Badr MZ, Taylor BK. Activation of peroxisome proliferator-activated receptor gamma in brain inhibits inflammatory pain, dorsal horn expression of Fos, and local edema. Neuropharmacology 2010;58:337-345. https:\/\/doi.org\/10.1016\/j.neuropharm.2009.10.008","DOI":"10.1016\/j.neuropharm.2009.10.008"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"47.\tWestlund KN, Zhang M. Building and testing therapeutic ELB00824 with an improved therapeutic window for neuropathic pain. Molecules 2020;25:1120. https:\/\/doi.org\/10.3390\/molecules25051120","DOI":"10.3390\/molecules25051120"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"48.\tYano M, Matsumura T, Senokuchi T, Ishii N, Murata Y, Taketa K, et al. Statins activate PPAR through ERK1\/2 and p38 MAPK-dependent COX-2 production in macrophages. Circ Res 2007;100:1442-1451. https:\/\/doi.org\/10.1161\/01.RES.0000268411.49545.9c","DOI":"10.1161\/01.RES.0000268411.49545.9c"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"49.\tPaumelle R, Blanquart C, Briand O, Barbier O, Duhem C, Woerly G, et al. Acute antiinflammatory properties of statins involve peroxisome proliferatoractivated receptor- via inhibition of the protein kinase C signaling pathway. Circ Res 2006;98:361-369. https:\/\/doi.org\/10.1161\/01.RES.0000202706.70992.95","DOI":"10.1161\/01.RES.0000202706.70992.95"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"50.\tGwak YS, Hassler SE, Hulsebosch CE. Reactive oxygen species contribute to neuropathic pain and locomotor dysfunction via activation of CamKII in remote segments following spinal cord contusion injury in rats. Pain 2013;154:1699-1708. https:\/\/doi.org\/10.1016\/j.pain.2013.05.018","DOI":"10.1016\/j.pain.2013.05.018"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"51.\tJaggi AS, Singh N. Therapeutic targets for the management of peripheral nerve injury-induced neuropathic pain. CNS Neurol Disord Drug Targets 2011;10:589-609. https:\/\/doi.org\/10.2174\/187152711796235041","DOI":"10.2174\/187152711796235041"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"52.\tHaendeler J, Hoffmann J, Zeiher AM, Dimmeler S. Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins. Circulation 2004;110:856-861. https:\/\/doi.org\/10.1161\/01.CIR.0000138743.09012.93","DOI":"10.1161\/01.CIR.0000138743.09012.93"}],"container-title":["Physiological Research"],"original-title":[],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:49:22Z","timestamp":1784720962000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.biomed.cas.cz\/physiolres\/pdf\/2026\/75_585.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":52,"URL":"https:\/\/doi.org\/10.33549\/physiolres.935681","relation":{},"ISSN":["1802-9973"],"issn-type":[{"value":"1802-9973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]}}}